Jaroslaw P. Maciejewski

43.0k total citations · 2 hit papers
678 papers, 21.1k citations indexed

About

Jaroslaw P. Maciejewski is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Jaroslaw P. Maciejewski has authored 678 papers receiving a total of 21.1k indexed citations (citations by other indexed papers that have themselves been cited), including 491 papers in Hematology, 254 papers in Genetics and 200 papers in Immunology. Recurrent topics in Jaroslaw P. Maciejewski's work include Acute Myeloid Leukemia Research (373 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (143 papers) and Hematopoietic Stem Cell Transplantation (82 papers). Jaroslaw P. Maciejewski is often cited by papers focused on Acute Myeloid Leukemia Research (373 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (143 papers) and Hematopoietic Stem Cell Transplantation (82 papers). Jaroslaw P. Maciejewski collaborates with scholars based in United States, Italy and Germany. Jaroslaw P. Maciejewski's co-authors include Neal S. Young, Mikkael A. Sekeres, Christine L. O’Keefe, Carmine Selleri, Ramón V. Tiu, Antonio M. Risitano, Hideki Makishima, Elaine M. Sloand, T Sato and Michael A. McDevitt and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Jaroslaw P. Maciejewski

644 papers receiving 20.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

2010 993 citations Jaroslaw P. Maciejewski et al. profile →
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

2006 878 citations Peter Hillmen, Neal S. Young et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jaroslaw P. Maciejewski United States	78	11.7k	7.4k	6.9k	6.2k	2.2k	678	21.1k
William Vainchenker France	91	16.7k 1.4×	4.9k 0.7×	11.9k 1.7×	11.8k 1.9×	3.8k 1.7×	569	29.2k
Franco Dammacco Italy	72	5.0k 0.4×	3.9k 0.5×	5.9k 0.9×	2.5k 0.4×	4.3k 2.0×	385	17.0k
Steven P. Treon United States	72	7.3k 0.6×	5.8k 0.8×	6.5k 0.9×	10.3k 1.7×	4.5k 2.1×	471	19.3k
Alberto Órfão Spain	66	5.4k 0.5×	5.8k 0.8×	4.5k 0.7×	3.4k 0.5×	3.1k 1.4×	463	16.1k
Attilio Orazi United States	49	8.8k 0.8×	2.4k 0.3×	4.5k 0.6×	6.8k 1.1×	2.8k 1.3×	281	16.1k
Robert P. Hasserjian United States	48	9.3k 0.8×	2.1k 0.3×	4.6k 0.7×	6.3k 1.0×	2.9k 1.3×	285	16.2k
David Dingli United States	64	8.0k 0.7×	970 0.1×	8.9k 1.3×	2.7k 0.4×	5.3k 2.4×	465	14.8k
James W. Vardiman United States	50	14.5k 1.2×	2.8k 0.4×	6.8k 1.0×	8.9k 1.4×	3.3k 1.5×	118	22.3k
Kenneth Kaushansky United States	61	7.6k 0.6×	2.9k 0.4×	3.8k 0.5×	3.1k 0.5×	2.3k 1.1×	210	12.9k
Robin Foà Italy	57	5.7k 0.5×	3.8k 0.5×	5.0k 0.7×	4.4k 0.7×	4.5k 2.0×	501	14.9k

Countries citing papers authored by Jaroslaw P. Maciejewski

Since Specialization

Citations

This map shows the geographic impact of Jaroslaw P. Maciejewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaroslaw P. Maciejewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaroslaw P. Maciejewski more than expected).

Fields of papers citing papers by Jaroslaw P. Maciejewski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaroslaw P. Maciejewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaroslaw P. Maciejewski. The network helps show where Jaroslaw P. Maciejewski may publish in the future.

Co-authorship network of co-authors of Jaroslaw P. Maciejewski

This figure shows the co-authorship network connecting the top 25 collaborators of Jaroslaw P. Maciejewski. A scholar is included among the top collaborators of Jaroslaw P. Maciejewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaroslaw P. Maciejewski. Jaroslaw P. Maciejewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fattizzo, Bruno, Carmelo Gurnari, Sabrina Giammarco, et al.. (2025). Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World. American Journal of Hematology. 100(4). 584–591. 3 indexed citations

Gu, Xiaorong, Simon Schlanger, Daniel Vail, et al.. (2023). Metabolic Signatures and Pathway Rewiring in TET2-Mutated Myeloid Neoplasia. Blood. 142(Supplement 1). 2747–2747.

Kongkiatkamon, Sunisa, Simona Pagliuca, Vera Ademà, et al.. (2021). Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. Leukemia. 36(4). 1185–1188. 3 indexed citations

Hershberger, Courtney E., Vera Ademà, Cassandra M Kerr, et al.. (2020). Complex landscape of alternative splicing in myeloid neoplasms. Leukemia. 35(4). 1108–1120. 37 indexed citations

Durrani, Jibran & Jaroslaw P. Maciejewski. (2019). Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome. Hematology. 2019(1). 97–104. 23 indexed citations

Poh, Weijie, Robert L. Dilley, Alison R. Moliterno, et al.. (2019). BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies. Clinical Cancer Research. 25(8). 2513–2522. 10 indexed citations

Molenaar, Remco J., Tomas Radivoyevitch, Yasunobu Nagata, et al.. (2018). IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. Clinical Cancer Research. 24(7). 1705–1715. 79 indexed citations

Hirsch, Cassandra M., Michael J. Clemente, Vera Ademà, et al.. (2017). High Frequency of Subclonal Myeloid Mutations Can be Found in Large Granular Lymphocyte Leukemia. Blood. 130. 1171–1171. 1 indexed citations

Molenaar, Remco J., Dennis Botman, Vashendriya V.V. Hira, et al.. (2015). Radioprotection of IDH1 -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Research. 75(22). 4790–4802. 116 indexed citations

10.

Nawrocki, Steffan T., Kevin R. Kelly, Peter G. Smith, et al.. (2014). The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine. Clinical Cancer Research. 21(2). 439–447. 39 indexed citations

11.

Mahfouz, Reda Z., Ania Jankowska, Quteba Ebrahem, et al.. (2013). Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy. Clinical Cancer Research. 19(4). 938–948. 105 indexed citations

12.

Nischal, Sangeeta, Sanchari Bhattacharyya, Maximilian Christopeit, et al.. (2012). Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms. Cancer Research. 73(3). 1076–1085. 42 indexed citations

13.

Makishima, Hideki & Jaroslaw P. Maciejewski. (2011). Pathogenesis and Consequences of Uniparental Disomy in Cancer. Clinical Cancer Research. 17(12). 3913–3923. 73 indexed citations

14.

Fischer, Annika, Gordon Brestrich, Marcin W. Włodarski, et al.. (2011). Cytomegalovirus-Specific Regulatory and Effector T Cells Share TCR Clonality—Possible Relation to Repetitive CMV Infections. American Journal of Transplantation. 12(3). 669–681. 40 indexed citations

15.

Sekeres, Mikkael A., Alan F. List, David Cuthbertson, et al.. (2010). Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology. 28(13). 2253–2258. 86 indexed citations

16.

Makishima, Hideki, Heather Cazzolli, Hadrian Szpurka, et al.. (2009). Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies. Journal of Clinical Oncology. 27(36). 6109–6116. 150 indexed citations

17.

Ye, Ying, Michael A. McDevitt, Mingzhou Guo, et al.. (2009). Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid Malignancies. Cancer Research. 69(21). 8482–8490. 35 indexed citations

18.

Makishima, Hideki, Lukasz P. Gondek, Jungwon Huh, et al.. (2009). FISH and SNP-A karyotyping in myelodysplastic syndromes: Improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). Leukemia Research. 34(4). 447–453. 53 indexed citations

19.

Dunbar, Andrew, Lukasz P. Gondek, Christine L. O’Keefe, et al.. (2008). 250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl , in Myeloid Malignancies. Cancer Research. 68(24). 10349–10357. 223 indexed citations

20.

Brodsky, Robert A., Neal S. Young, Elisabetta Antonioli, et al.. (2007). Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 111(4). 1840–1847. 457 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact